NCT02302989View on ClinicalTrials.gov

Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions
Age-related Macular Degeneration
Interventions
DRUG

Ranibizumab 0.5mg

Trial Locations (2)

07666

NJ Retina (Retina Associates of New Jersey), Teaneck

07088

NJ Retina (Retina Associates of New Jersey), Vauxhall

All Listed Sponsors
collaborator

NJ Retina (Retina Associates of New Jersey)

OTHER

lead

Leonard Feiner, MD, PhD

OTHER

NCT02302989 - Prophylactic Ranibizumab for Exudative Age-Related Macular Degeneration | Biotech Hunter | Biotech Hunter